Search PCRX
Pacira BioSciences, Inc.
Nasdaq · CIK 1396814
Last close25.21
Daily change+0.20 (0.80%)
10 Years gain-29.58%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PCRX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
44.8Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue17
Quarterly Revenue70
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.5 / 25
Quality13.5 / 25
Capital Efficiency3.2 / 20
Balance Sheet10.5 / 15
Shareholder Economics9.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.8285 percentage points.
Operating leverageOperating margin improved by 17.6394 percentage points.
Share count reductionDiluted share count declined 13.3818%.
Key Metrics
Revenue Growth TTM7%OK
Revenue CAGR 3Y2.89%OK
Gross Margin78.68%OK
Operating Margin3.56%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC2.02%OK
Incremental Operating Margin 3Y-33.83%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-13.38%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $726.41M | $576.66M | $19.19M | $151.99M | $136.66M | 79.39% | 2.64% | 18.81% | 1.46% | 45.04M |
| 2025 FY Dec 31, 2024 | $700.97M | $530.54M | -$73.37M | $189.39M | $178.75M | 75.69% | -10.47% | 25.5% | -5.82% | 46.25M |
| 2025 FY Dec 31, 2023 | $674.98M | $490.31M | $87.68M | $154.65M | $139.49M | 72.64% | 12.99% | 20.67% | n/a | 51.98M |
| 2024 FY Dec 31, 2022 | n/a | $399.34M | $60.02M | $145.27M | $115.20M | n/a | n/a | n/a | n/a | 46.54M |
| 2023 FY Dec 31, 2022 | $666.82M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $730.39M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-052635, 0001628280-25-050176 |
| Revenue Growth TTM | 7% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-052635, 0001628280-25-050176 |
| Revenue CAGR 3Y | 2.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012297 |
| Revenue CAGR 5Y | 11.07% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-012297 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-012297 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-052635, 0001628280-25-050176 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 78.68% | Gross Profit / Revenue | OK | 0001628280-26-052635, 0001628280-25-050176 |
| Operating Margin | 3.56% | Operating Income / Revenue | OK | 0001628280-26-052635, 0001628280-25-050176 |
| ROIC | 2.02% | NOPAT / Average Invested Capital | OK | 0001628280-26-052635, 0001628280-25-050176 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-052635 |
| Current Ratio | 5.04x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.69x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-052635 |
| Revenue per Diluted Share | $18.12 | Revenue / Diluted Shares | OK | 0001628280-26-052635, 0001628280-25-050176 |